Cargando…

Precise Epigenetic Analysis Using Targeted Bisulfite Genomic Sequencing Distinguishes FSHD1, FSHD2, and Healthy Subjects

The true prevalence of facioscapulohumeral muscular dystrophy (FSHD) is unknown due to difficulties with accurate clinical evaluation and the complexities of current genetic diagnostics. Interestingly, all forms of FSHD are linked to epigenetic changes in the chromosome 4q35 D4Z4 macrosatellite, sug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gould, Taylor, Jones, Takako I., Jones, Peter L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393475/ https://www.ncbi.nlm.nih.gov/pubmed/34441403 http://dx.doi.org/10.3390/diagnostics11081469

Ejemplares similares

Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD
por: Himeda, Charis L., et al.
Publicado: (2020)

Genotype-phenotype correlations in FSHD
por: Zernov, Nikolay, et al.
Publicado: (2019)

Current Therapeutic Approaches in FSHD
por: Wang, Leo H., et al.
Publicado: (2021)

Therapeutic Strategies Targeting DUX4 in FSHD
por: Le Gall, Laura, et al.
Publicado: (2020)

FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?
por: Himeda, Charis L., et al.
Publicado: (2022)

Does DNA Methylation Matter in FSHD?
por: Salsi, Valentina, et al.
Publicado: (2020)

Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
por: Lu-Nguyen, Ngoc, et al.
Publicado: (2021)

Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Jones, Takako I., et al.
Publicado: (2016)

UK Facioscapulohumeral Muscular Dystrophy (FSHD) Patient Registry
por: Wood, Libby, et al.
Publicado: (2014)

Gene expression during normal and FSHD myogenesis
por: Tsumagari, Koji, et al.
Publicado: (2011)

Cardiac Involvement in Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Ducharme-Smith, Allison, et al.
Publicado: (2021)

Expression Profiling of FSHD-1 and FSHD-2 Cells during Myogenic Differentiation Evidences Common and Distinctive Gene Dysregulation Patterns
por: Cheli, Stefania, et al.
Publicado: (2011)

FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1
por: Mellion, M., et al.
Publicado: (2020)

DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation
por: Banerji, Christopher R S, et al.
Publicado: (2020)

Designed U7 snRNAs inhibit DUX4 expression and improve FSHD-associated outcomes in DUX4 overexpressing cells and FSHD patient myotubes
por: Rashnonejad, Afrooz, et al.
Publicado: (2020)

FSHD: copy number variations on the theme of muscular dystrophy
por: Cabianca, Daphne Selvaggia, et al.
Publicado: (2010)

FSHD Myotubes with Different Phenotypes Exhibit Distinct Proteomes
por: Tassin, Alexandra, et al.
Publicado: (2012)

Functional domains of the FSHD-associated DUX4 protein
por: Mitsuhashi, Hiroaki, et al.
Publicado: (2018)

Meeting report: the 2021 FSHD International Research Congress
por: Jagannathan, Sujatha, et al.
Publicado: (2022)

Meeting report: the 2020 FSHD International Research Congress
por: Kyba, Michael, et al.
Publicado: (2020)

The FSHD jigsaw: are we placing the tiles in the right position?
por: Salsi, Valentina, et al.
Publicado: (2023)

PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level
por: Banerji, Christopher R S, et al.
Publicado: (2019)

Next-Generation Sequencing Analysis of MiRNA Expression in Control and FSHD Myogenesis
por: Colangelo, Veronica, et al.
Publicado: (2014)

Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?
por: Joubert, Romains, et al.
Publicado: (2020)

The FSHD Atrophic Myotube Phenotype Is Caused by DUX4 Expression
por: Vanderplanck, Céline, et al.
Publicado: (2011)

Culture Conditions Affect Expression of DUX4 in FSHD Myoblasts
por: Pandey, Sachchida Nand, et al.
Publicado: (2015)

Are Antioxidants a Potential Therapy for FSHD? A Review of the Literature
por: Denny, Adam Philip, et al.
Publicado: (2017)

Orofacial Muscle Weakening in Facioscapulohumeral Muscular Dystrophy (FSHD) Patients
por: Konstantonis, Dimitrios, et al.
Publicado: (2022)

DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy
por: Mocciaro, Emanuele, et al.
Publicado: (2021)

Update on the Molecular Aspects and Methods Underlying the Complex Architecture of FSHD
por: Caputo, Valerio, et al.
Publicado: (2022)

Gastrointestinal cancer occurs as extramuscular manifestation in FSHD1 patients
por: Kurashige, Takashi, et al.
Publicado: (2022)

Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD): A Systematic Review
por: Aguirre, Alex S, et al.
Publicado: (2023)

Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation
por: Bodega, Beatrice, et al.
Publicado: (2009)

Direct interplay between two candidate genes in FSHD muscular dystrophy
por: Ferri, Giulia, et al.
Publicado: (2015)

miRNA Expression in Control and FSHD Fetal Human Muscle Biopsies
por: Portilho, Débora Morueco, et al.
Publicado: (2015)

Facioscapulohumeral muscular dystrophy (FSHD) and multiple sclerosis: a case report
por: Iodice, Rosa, et al.
Publicado: (2020)

The variability of SMCHD1 gene in FSHD patients: evidence of new mutations
por: Strafella, Claudia, et al.
Publicado: (2019)

MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy
por: Runfola, Valeria, et al.
Publicado: (2023)

Intrinsic Epigenetic Regulation of the D4Z4 Macrosatellite Repeat in a Transgenic Mouse Model for FSHD
por: Krom, Yvonne D., et al.
Publicado: (2013)

miR-411 is up-regulated in FSHD myoblasts and suppresses myogenic factors
por: Harafuji, Naoe, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g1th4rq22cvo5dflesr8u6cta0